SECUKINUMAB PROVIDES SUSTAINED IMPROVEMENTS IN THE SIGNS AND SYMPTOMS OF ACTIVE PSORIATIC ARTHRITIS: 2-YEAR EFFICACY AND SAFETY RESULTS FROM THE PHASE 3 RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED TRIAL, FUTURE 1 - Kavanaugh, A.; Mease, P.; Reimold, A.; Tahir, H.; Rech, Jürgen; Hall, S.; Geusens, P.; Wang, Z.; Mpofu, S. (2016)
EVALuna2:35076